Maze Therapeutics secures US$115M in Series D financing

USA—Maze Therapeutics, a biotechnology company focused on developing genetic-based therapies, has successfully completed a Series D financing round, raising US$115 million.

The funds will support the development of the company’s two leading drug candidates, MZE829 and MZE782, both of which show promise in treating kidney diseases.

The financing round was co-led by Deep Track Capital and Frazier Life Sciences, with participation from Logos Capital and Janus Henderson Investors.

 Existing investors, including ARCH Venture Partners, Third Rock Ventures, GV, Matrix Capital Management, General Catalyst, and Woodline Partners, also contributed to the round.

This financing included the conversion of convertible notes previously held by these investors, further solidifying their support for Maze’s innovative pipeline.

MZE829, an oral inhibitor targeting the APOL1 gene, is being evaluated for its potential to treat APOL1-related kidney diseases, particularly focal segmental glomerulosclerosis (FSGS).

This condition, which is characterized by damage to the kidneys’ filtering units, often leads to kidney failure.

Maze plans to initiate a Phase II clinical trial for MZE829 by the first quarter of 2025, which will help assess its efficacy in treating this challenging disease.

In addition to MZE829, Maze is advancing MZE782, an oral inhibitor of the SCL6A19 protein.

This candidate is currently undergoing a Phase I trial in healthy volunteers. Maze intends to explore MZE782 as a potential treatment for chronic kidney disease and phenylketonuria (PKU), a rare genetic disorder that can lead to developmental delays if untreated. The company expects to release Phase I trial results for MZE782 in the latter half of 2025.

Maze’s CEO, Jason Coloma, expressed gratitude for the continued backing from long-term investors, emphasizing the company’s excitement about the new partners joining the effort.

“We are thrilled to welcome the teams from Frazier, Deep Track, and Logos as we advance our two lead clinical programs and continue to leverage our Compass platform to uncover new biological pathways tied to disease,” he remarked.

This financing round marks a significant milestone for Maze Therapeutics, not only in expanding its research but also in ensuring resources are in place to move these critical clinical trials forward.

The company’s unique Compass platform, which uses genetic insights to identify disease pathways, continues to guide its work, aiming to improve outcomes for patients suffering from complex conditions.

In May 2023, Maze also entered into an exclusive worldwide license agreement with Sanofi for its glycogen synthase 1 (GYS1) program, which focuses on developing an oral therapy for Pompe disease, further expanding the company’s pipeline and strategic partnerships.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.